Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes

Part of paid clinical trials in Charlottesville, Virginia.

Sponsor
University of Virginia
Study ID
NCT07186660
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cardiovascular Health
  • Glycemic Control for Diabetes Mellitus
  • Insulin
  • Ketones
  • Type 1 Diabetes (T1D)

Eligibility Criteria

Sex
ALL
Age
18 Years - 45 Years
Healthy Volunteers
Not accepted

Interventions

  • CIR-0602K — DRUG
    mitochondrial pyruvate carrier inhibitor
  • Placebo — DRUG
    Placebo tablet

Study Details

The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and/or lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery. Researchers will compare CIR-0602K to a placebo (a look-alike substance that contains no drug) to see if it achieves the investigational endpoints. If the study results show that the drug works to increase time-in-range and lower insulin doses, this will lead to further studies which may then make the drug available to the public.

Key Dates

Start date
Feb 22, 2026
Status verified
Feb 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: CIR-0602K
    CIR-0602K 250 mg daily
  • Placebo Comparator: Placebo
    Matching Placebo Tablet

Primary Outcome Measure

Glucose Time-in-Range [ Time Frame: 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of VirginiaCharlottesvilleVirginia22908
Horton B Horton, MD
[email protected]
(434) 924-1828

Find similar trials in Charlottesville, VA

By research site
University of Virginia· Charlottesville, VA

Related Studies